Ginkgo Bioworks Holdings (DNA) Profit After Tax Growth (1y) (2021 - 2026)

Ginkgo Bioworks Holdings (DNA) Profit After Tax Growth (1y) (2021 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) PAT Growth (1y) (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - 0.26%
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 17,802.13%
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 59.59%
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn -107.76%
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn 101.22%
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 Ginkgo Bioworks Holdings 445.24 Mn 301.37 Mn 16.38 Mn 0.87%

Historic Data

Download Data
DateValue
Mar 31, 2026 0.87%
Dec 31, 2025 -46.99%
Sep 30, 2025 -43.18%
Jun 30, 2025 73.41%
Mar 31, 2025 49.79%
Dec 31, 2024 306.63%
Sep 30, 2024 81.38%
Jun 30, 2024 -25.64%
Mar 31, 2024 18.65%
Dec 31, 2023 -20.65%
Sep 30, 2023 54.80%
Jun 30, 2023 74.20%
Mar 31, 2023 65.46%
Dec 31, 2022 89.09%
Sep 30, 2022 -554.39%
Jun 30, 2022 -1,143.15%
Mar 31, 2022 -702.65%
Dec 31, 2021 -3,367.67%
Sep 30, 2021 -293.03%